Kanakavarshini Biologics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.42 M
- Company Age 16 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -22.66%
- Profit Growth 15.29%
- Ebitda -20.40%
- Net Worth 19.44%
- Total Assets 11.95%
About Kanakavarshini Biologics
Kanakavarshini Biologics Private Limited (KBPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 November 2008 and has a history of 16 years and two months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.42 M, as per Ministry of Corporate Affairs (MCA) records.
Raghunandhan Cancherla, Harini, and Cancherla Shreyes serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33110TN2008PTC070007
-
Company No.
070007
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Nov 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Kanakavarshini Biologics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghunandhan Cancherla
|
Managing Director | 27-Nov-2008 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Harini
|
Director | 03-Aug-2023 | Current |
|
Cancherla Shreyes
|
Director | 03-Aug-2023 | Current |
Financial Performance of Kanakavarshini Biologics.
Kanakavarshini Biologics Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 22.66% decrease. The company also saw a substantial improvement in profitability, with a 15.29% increase in profit. The company's net worth Soared by an impressive increase of 19.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kanakavarshini Biologics?
In 2017, Kanakavarshini Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kanakavarshini Biologics?
Unlock and access historical data on people associated with Kanakavarshini Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kanakavarshini Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kanakavarshini Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
